Disclosed are immunogenic compositions and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, and/or ameliorating the symptoms of one o
Disclosed are immunogenic compositions and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular, the invention provides immunogenic compositions and methods for preventing, treating, and/or ameliorating the symptoms of one or more microbial infections, including, for example, influenza.
대표청구항▼
1. A non-natural immunogenic fusion peptide or polypeptide comprising the following in any order: at least two separate antigenic influenza peptide epitopes, wherein each of the separate epitopes is from 7 to about 70 amino acids in length, and wherein each separate epitopes comprises the amino acid
1. A non-natural immunogenic fusion peptide or polypeptide comprising the following in any order: at least two separate antigenic influenza peptide epitopes, wherein each of the separate epitopes is from 7 to about 70 amino acids in length, and wherein each separate epitopes comprises the amino acid sequence of any one of SEQ ID NOs: 18, 19, 49, 50, 51, and 52; andat least one T-cell stimulating epitope from a tetanus toxoid, a diphtheria toxoid, a polysaccharide, a lipoprotein, or any combination thereof, wherein the at least one T-cell stimulating epitope is not derived from influenza virus. 2. The immunogenic peptide or polypeptide of claim 1, further comprising an amino acid sequence that is at least 95% identical to the sequence of any one of SEQ ID NO: 1-75. 3. The immunogenic peptide or polypeptide of claim 1, further comprising the amino acid sequence of any one of SEQ ID NO: 1-75. 4. The immunogenic peptide or polypeptide of claim 1, wherein the T-cell stimulating epitope comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 53. 5. An isolated polynucleotide that encodes the immunogenic fusion peptide or polypeptide of claim 1. 6. An expression vector that comprises the isolated polynucleotide of claim 5. 7. The expression vector of claim 6, wherein the polynucleotide is operably linked to a promoter. 8. The immunogenic fusion peptide or polypeptide of claim 1, formulated for administration to a mammalian host cell. 9. The immunogenic fusion peptide or polypeptide of claim 1, formulated for systemic or local administration to a human. 10. The immunogenic peptide or polypeptide of claim 1, further comprising an adjuvant. 11. The immunogenic peptide or polypeptide of claim 1, further comprising an ethosome, a lipid complex formed from at least one different lipid, a liposome, a niosome, a phospholipid, a sphingosome, a surfactant, a transferosome, or any combination thereof. 12. The immunogenic peptide or polypeptide of claim 1, comprised within a microcapsule, microparticle, microsphere, nanocapsule, nanoparticle, nanosphere, or a combination thereof. 13. A non-natural immunogenic fusion peptide or polypeptide comprising the following in any order: at least two separate antigenic influenza peptide epitopes, wherein each separate epitope comprises the amino acid sequence of any one of SEQ ID NOs: 18, 19, 49, 50, 51, and 52; andat least one T-cell stimulating epitope from a tetanus toxoid, a diphtheria toxoid, a polysaccharide, a lipoprotein, or any combination thereof, wherein the at least one T-cell stimulating epitope is not derived from influenza virus. 14. The immunogenic peptide or polypeptide of claim 13, wherein at least two of the antigenic epitopes are repeated and either multimeric, collinearly expressed, or chemically crosslinked. 15. The immunogenic peptide or polypeptide of claim 13, further comprising a type 14 pneumococcal polysaccharide. 16. The immunogenic peptide or polypeptide of claim 13, further comprising a protein or polysaccharide derived from Streptococcus or Staphylococcus bacteria. 17. The immunogenic peptide or polypeptide of claim 13, wherein the at least one T-cell stimulating epitope comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 53. 18. A therapeutic or diagnostic kit in a suitable container, wherein said kit comprises: a composition, wherein said composition comprises: (i) the non-natural immunogenic fusion peptide or polypeptide of claim 1(ii) an isolated polynucleotide encoding the peptide or polypeptide of claim 1;(iii) an expression vector, a viral vector, or a reassortant, killed, attenuated, or inactivated virus comprising a polynucleotide encoding the peptide or polypeptide of claim 1;(iv) an antibody or antigen binding fragment that specifically binds to the peptide or polypeptide of claim 1; or(v) any combination thereof. 19. A peptide comprising the sequence of SEQ ID NO: 18, 49, 50, 51, or 52 and a T-cell stimulating epitope, wherein the T-cell stimulating epitope comprises a tetanus toxoid, a diphtheria toxoid, a polysaccharide, a lipoprotein, an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 53, or any combination thereof. 20. The peptide of claim 19, further comprising an amino acid sequence that is at least 95% identical to the sequence of any one of SEQ ID NO: 1-75. 21. The peptide of claim 19, further comprising the amino acid sequence of any one of SEQ ID NO: 1-75. 22. A therapeutic or diagnostic kit comprising: a composition, wherein said composition comprises: (i) the non-natural immunogenic fusion peptide or polypeptide of claim 19;(ii) an isolated polynucleotide encoding the peptide or polypeptide of claim 19;(iii) an expression vector, a viral vector, or a reassortant, killed, attenuated, or inactivated virus comprising a polynucleotide encoding the peptide or polypeptide of claim 19;(iv) an antibody or antigen binding fragment that specifically binds to the peptide or polypeptide of claim 19; or(v) any combination thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (150)
Liav Avraham ; Hansjergen Joyce Anne ; Shimasaki Craig David, 4,7-dialkoxy N-acetylneuraminic acid derivatives and methods for detection of influenza type A and B viruses in clinic.
Bridgham John (Palo Alto CA) Geiser Timothy G. (La Honda CA) Hunkapiller Michael W. (San Carlos CA) Kent Stephen B. H. (Pasadena CA) Marriott Mark P. (Los Altos CA) Ramstad Paul O. (Oakland CA) Nordm, Automated polypeptide synthesis apparatus.
Bridgham John (Palo Alto CA) Geiser Timothy G. (La Honda CA) Hunkapiller Michael W. (San Carlos CA) Kent Stephen B. H. (Pasadena CA) Marriott Mark P. (Los Altos CA) Ramstad Paul O. (Oakland CA) Nordm, Automated polypeptide synthesis apparatus.
Bridgham John (Palo Alto CA) Geiser Timothy G. (La Honda CA) Hunkapiller Michael W. (San Carlos CA) Kent Stephen B. H. (Pasadena CA) Marriott Mark P. (Los Altos CA) Ramstad Paul O. (Oakland CA) Nordm, Automated polypeptide synthesis process.
Gayral, Jean Pierre; Picard, Francois; Boissinot, Maurice; Bastien, Martine, Biological reagents and methods to verify the efficiency of sample preparation and nucleic acid amplification and/or detection.
Monthony James F. (Baltimore MD) Stitt David T. (Parkton MD) Gosnell C. Michael (Fallston MD) Stewart Shannon D. (Stewartstown PA), Biological sample collection and transport device.
Bair, Jr., Robert Jackson; Heath, Ellen M.; Meehan, Heather; Paulsen, Kim Elayne; Wages, Jr., John M., Compositions and methods for using a solid support to purify RNA.
Cerutti Peter A. (Poly/Lausanne CHX) Bressoud Albric (Lausanne CHX), Detection of influenza a virus by polymerase chain reaction (PCR) preceded by reverse transcription of a region of the v.
Whiteley Norman M. (San Carlos CA) Hunkapiller Michael W. (San Carlos CA) Glazer Alexander N. (Orinda CA), Detection of specific sequences in nucleic acids.
Doyle Michael V. (Oakland CA) Newell Arthur D. (Orinda CA) Nunberg Jack H. (Oakland CA) White Thomas J. (Oakland CA), Human IL-2 as a vaccine adjuvant.
Hunter Kenneth W. (4401 Dresden St. Kensington MD 20895) Fischer Gerald W. (10748 Wayridge Dr. Gaithersburg MD 20879), Human monoclonal antibody reactive with polyribosylribitol phosphate.
Heller Michael J. (Encinitas CA), Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to donor energy transfe.
Sette, Alessandro; Sidney, John; Southwood, Scott; Vitiello, Maria A.; Livingston, Brian D.; Celis, Esteban; Kubo, Ralph T.; Grey, Howard M.; Chesnut, Robert W., Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions.
Liav Avraham ; Shimasaki Craig D. ; Maher James F. ; Clinkscales C. Worth ; Roark Michael D., Kit for visually detecting the presence of a clinical specimen.
Yagi Kunio (Aichi-ken JPX) Noda Hitoshi (Aichi-ken JPX) Ohishi Nobuko (Gifu JPX) Kurono Masayasu (Mie-ken JPX), Liposome for entrapping gene, liposomal preparation and process for the manufacture of the preparation.
Liav Avraham (Denver CO) Maher James F. (Broken Arrow OK) Shimasaki Craig D. (Tulsa OK) Clinkscales C. Worth (Tulsa OK) Roark Michael D. (Owasso OK), Method for visually detecting the presence of a virus in a clinical specimen.
Reece Phillip A.,AUX ; Wu Wen-Yang,AUX ; Jin Betty,AUX ; Krippner Guy Y.,AUX ; Watson Keith Geoffrey,AUX, Method of detection of influenza virus and compounds for use therein.
Turner Gregory A. (Independence MO) Maher James F. (Broken Arrow OK) Clinkscales C. Worth (Tulsa OK) Roark Michael D. (Owasso OK), Methods for diagnosing human influenza and 4-position modified chromogenic N-acetylneuraminic acid substrated for use th.
Fischer, Gerald W.; Schuman, Richard F.; Wong, Hing; Stinson, Jeffrey R., Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria.
Fischer, Gerald W.; Schuman, Richard F.; Wong, Hing; Stinson, Jeffrey R., Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria.
Monthony James F. (Baltimore MD) Stitt David T. (Parkton MD) Gosnell C. Michael (Fallston MD) Stewart Shannon D. (Stewartstown PA), Polyurethane biological sample collection and transport device and its use.
Mullis Kary B. (La Jolla CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or cloning nucleic acid sequences.
Mullis Kary B. (Kensington CA) Erlich Henry A. (Oakland CA) Arnheim Norman (Woodland Hills CA) Horn Glenn T. (Emeryville CA) Saiki Randall K. (Richmond CA) Scharf Stephen J. (Berkeley CA), Process for amplifying, detecting, and/or-cloning nucleic acid sequences.
Boom Willem R. (Amsterdam NLX) Adriaanse Henritte M. A. (Arnhem NLX) Kievits Tim (The Hague NLX) Lens Peter F. (Amsterdam NLX), Process for isolating nucleic acid.
Fell ; Jr. H. Perry (Redmond WA) Folger-Bruce Kim R. (Seattle WA) Yarnold Susan M. (Seattle WA), Production of chimeric antibodies by homologous recombination.
Crawford Jack T. (Atlanta GA) Eisenach Kathleen D. (Little Rock AR) Cave M. Donald (Little Rock AR) Bates Joseph H. (Little Rock AR), Repetitive DNA sequence specific for mycobacterium tuberculosis to be used for the diagnosis of tuberculosis.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Judd Amrit K. (Belmont CA) Bucher Doris J. (New York NY) Popple Steven W. (Brooklyn NY), Synthetic peptides for diagnosis and prevention of influenza virus infection and their use.
Picard,Francois J.; Menard,Christian, Universal method and composition for the rapid lysis of cells for the release of nucleic acids and their detection.
van Scharrenburg, Gustaaf J. M.; Brands, Rudi; de Haan, Lolke; Verweij, Willem Ronald; Wilschut, Jan C.; Agsteribbe, Etienne, Vaccines with an LTB adjuvant.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.